Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <i>MET</i> -Amplified Esophagogastric Cancer
Eunice L. Kwak(Harvard University), Ryan B. Corcoran(Massachusetts General Hospital), Giulia Siravegna(University of Turin), Theodore S. Hong(Massachusetts General Hospital), Leanne G. Ahronian(Harvard University), A. John Iafrate(Massachusetts General Hospital), Alberto Bardelli(IFOM), Jochen K. Lennerz(Addgene), David P. Ryan(East Carolina University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Jason T. Godfrey(University of Pennsylvania), Nicholas A. Jessop(Massachusetts General Hospital), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Benedetta Mussolin(Candiolo Cancer Institute)
Cited by 168
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k